InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Alleva Lawrence M, Director. Officer active across 4 companies, notably Adaptimmune Therapeutics PLC. Aggregated, 9 disclosures have been logged. Total volume traded: €98k. The latest transaction was disclosed on 1 June 2021 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations9 total
1,299 shares
Common Stock
SEC:0001562180-22-005325:0·
671 shares
Common Stock
SEC:0001562180-21-004517·
671 shares
Common Stock
SEC:0001562180-21-004517:0·
€8,14712,600 shares@ €0.6466100.0% of flow
Ordinary Shares with a nominal value of GBP0.001 per share
SEC:0001104659-21-076401·
Ideal exit: 26 Feb 2022 (T+270)
€12,1821,035 shares@ €11.7697100.0% of flow
Common Stock
SEC:0001104659-21-076535·
Ideal exit: 26 Feb 2022 (T+270)
€28,4354,045 shares@ €7.0297100.0% of flow
Common Stock
SEC:0000899243-21-021824·
Ideal exit: 26 Feb 2022 (T+270)
€8,14712,600 shares@ €0.646650.0% of flow
Ordinary Shares with a nominal value of GBP0.001 per share
SEC:0001104659-21-076401:0·
Ideal exit: 26 Feb 2022 (T+270)
€28,4354,045 shares@ €7.02970.18% mcap50.0% of flow
Common Stock
SEC:0000899243-21-021824:0·
Ideal exit: 26 Feb 2022 (T+270)
€12,1821,035 shares@ €11.769750.0% of flow
Common Stock
SEC:0001104659-21-076535:0·
Ideal exit: 26 Feb 2022 (T+270)
9 of 9 declarations
About Alleva Lawrence M
Lawrence M Alleva is a Board Member at Adaptimmune Therapeutics PLC, Mersana Therapeutics, Inc., and Galera Therapeutics, Inc. He plays a key role in the governance of these biopharmaceutical companies, contributing to strategy development and informed decision-making. His expertise in biotechnology is an asset to the boards.
